Morbi et tellus imperdiet, aliquam nulla sed, dapibus erat. Aenean dapibus sem non purus venenatis vulputate. Donec accumsan eleifend blandit. Nullam auctor ligula

Get In Touch

Quick Email
info.help@gmail.com
  • Home |
  • J&J axes $5B CAR-T dream months after touting best-in-disease efficacy

J&J axes $5B CAR-T dream months after touting best-in-disease efficacy

  • May 1, 2026

Johnson & Johnson has dropped a pair of CAR-T cell therapies, axing programs it once predicted could deliver peak sales north of $5 billion.

Leave A Comment

Fields (*) Mark are Required